Compare Johnson & Johnson (JNJ) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Target Corporation — how do they compare? Johnson & Johnson trades at $248.46 (market cap $598.96B), while Target Corporation trades at $140 (market cap $63.40B). The key difference: Johnson & Johnson is far larger — about 9.4× Target Corporation's market cap, and Target Corporation pays the higher dividend (3.32%). Which is the better fit depends on your goals.
| JNJ | TGT | |
|---|---|---|
Market Cap | $598.96B | $63.40B |
Volume | 6,156,228 | — |
Sector | Health | Consumer Cyclical |
52-Week High | $267.24 | $141.19 |
52-Week Low | $164.36 | $83.68 |
Enterprise Value | $631.90B | $78.70B |
Dividend Yield | 2.15% | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Target (TGT) trades at $139.11, down 0.37% on the day, with a bullish technical outlook supported by moving averages and recent earnings beats. The stock shows solid fundamentals with a P/E of 18.44, P/S of 0.6, and ROE of 22.02%, while revenue remains stable around $106 billion. Positive sentiment is driven by improved traffic trends and merchandising updates noted by Jefferies on July 15, 2026.
Target presents a balanced opportunity with strong profitability and analyst support, though risks include competitive retail pressures and margin volatility. The consensus price target of $137 suggests limited upside, but consistent dividend payments and operational cash flow near $7.4 billion provide stability. Execution on merchandising initiatives will be key for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
